文献速递泌尿男性生殖肿瘤

前列腺癌转移灶全基因组研究:Wnt通路激活与细胞周期增殖增高关联AA/P原发耐药

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.
PubMed 文献 · Ann Oncol · 2018-01-01

一项前瞻性临床试验对mCRPC患者转移灶行全外显子测序(n=82)和RNA测序(n=75),旨在识别与阿比特龙/泼尼松(AA/P)耐药相关的基因组改变。12周时32例进展(非应答者),非应答者中Wnt/β-catenin通路基因突变更频繁、负调控因子缺失或mRNA表达降低,细胞周期调控基因mRNA表达增高。多变量模型中细胞周期增殖评分≥50与更短TTTC相关(HR=2.11,95%CI 1.17-3.80;P=0.01)。

要点

  • 非应答者Wnt/β-catenin通路基因突变更频繁,负调控因子缺失或mRNA表达降低。
  • 非应答者细胞周期调控基因mRNA表达增高。
  • 细胞周期增殖评分≥50与更短TTTC相关(HR=2.11,95%CI 1.17-3.80;P=0.01)。

核心结论

  • Wnt/β-catenin通路激活和细胞周期进展评分增高可作为预测AA/P治疗耐药的分子标志物。

研究设计与样本

  • 前瞻性临床试验,mCRPC患者开始AA/P治疗前对转移灶行全外显子测序(n=82)和RNA测序(n=75)。
  • 原发耐药在治疗12周时判定,标准包括血清PSA、骨和CT影像及症状评估。
  • 获得性耐药以治疗更换时间(TTTC)为终点,定义为从入组至因疾病进展更换治疗的时间。

主要发现

  • 12周时队列中32例患者进展(非应答者)。
  • 中位随访32.1个月,期间58例患者因进展更换治疗。
  • 中位TTTC为10.1个月(四分位距:4.4-24.1)。
  • 非应答者中Wnt/β-catenin通路基因突变更频繁,Wnt/β-catenin信号负调控因子缺失或mRNA表达降低更频繁。
  • 非应答者细胞周期调控基因mRNA表达增高;多变量模型中细胞周期增殖评分≥50与更短TTTC相关(HR=2.11,95%CI 1.17-3.80;P=0.01)。

关键数值与推荐

  • 原发耐药判定标准:治疗12周时根据血清PSA、骨和CT影像及症状评估判定进展。
  • 获得性耐药终点TTTC:从入组至因疾病进展更换治疗的时间。
  • 细胞周期增殖评分≥50与更短TTTC相关(HR=2.11,95%CI 1.17-3.80;P=0.01)。

临床怎么用

  • Wnt/β-catenin通路激活和细胞周期增殖评分增高或可作为预测AA/P耐药的分子标志物。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genomic aberrations have been identified in metastatic castration-resistant prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known. PATIENTS AND METHODS: In a prospective clinical trial, mCRPC patients underwent whole-exome sequencing (n = 82) and RNA sequencing (n = 75) of metastatic biopsies before initiating AA/P with the objective of identifying genomic alterations associated with resistance to AA/P. Primary resistance was determined at 12 weeks of treatment using criteria for progression that included serum prostate-specific antigen measurement, bone and computerized tomography imaging and symptom assessments. Acquired resistance was determined using the end point of time to treatment change (TTTC), defined as time from enrollment until change in treatment from progressive disease. Associations of genomic and transcriptomic alterations with primary resistance were determined using logistic regression, Fisher's exact test, single and multivariate analyses. Cox regression models were utilized for determining association of genomic and transcriptomic alterations with TTTC. RESULTS: At 12 weeks, 32 patients in the cohort had progressed (nonresponders). Median study follow-up was 32.1 months by which time 58 patients had switched treatments due to progression. Median TTTC was 10.1 months (interquartile range: 4.4-24.1). Genes in the Wnt/β-catenin pathway were more frequently mutated and negative regulators of Wnt/β-catenin signaling were more frequently deleted or displayed reduced mRNA expression in nonresponders. Additionally, mRNA expression of cell cycle regulatory genes was increased in nonresponders. In multivariate models, increased cell cycle proliferation scores (≥ 50) were associated with shorter TTTC (hazard ratio = 2.11, 95% confidence interval: 1.17-3.80; P = 0.01). CONCLUSIONS: Wnt/β-catenin pathway activation and increased cell cycle progression scores can serve as molecular markers for predicting resistance to AA/P therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wang L, Dehm SM, Hillman DW, et al. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018. PMID: 29069303. doi:10.1093/annonc/mdx689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。